The adaptive stroma joining the antiangiogenic resistance front

被引：12

作者：

Casanovas, Oriol ^{[1
]}

机构：

[1] Catalan Inst Oncol IDIBELL, Translat Res Lab, Tumor Angiogenesis Grp, E-08907 Lhospitalet De Llobregat, Spain

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2011年 / 121卷 / 04期

关键词：

ENDOTHELIAL GROWTH-FACTOR; TUMOR REFRACTORINESS; ANGIOGENESIS; THERAPY; PERICYTES; VASCULATURE; PATHWAYS; DISEASE;

D O I：

10.1172/JCI46430

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non-small cell lung carcinoma (NSCLC) models that include EGFR-driven vascular remodeling promoting resistance to VEGF inhibition. Their results suggest that the added benefit of dual VEGF/R and EGFR targeting in these models could be clinically relevant to fight resistance in NSCLC patients.

引用

页码：1244 / 1247

页数：4

共 21 条

[1] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[2] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[3] Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].

Boehm, T ;

Folkman, J ;

Browder, T ;

OReilly, MS .

NATURE, 1997, 390 (6658) :404-407

[4] Angiogenesis in life, disease and medicine [J].

Carmeliet, P .

NATURE, 2005, 438 (7070) :932-936

[5] Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma [J].

Cascone, Tina ;

Herynk, Matthew H. ;

Xu, Li ;

Du, Zhiqiang ;

Kadara, Humam ;

Nilsson, Monique B. ;

Oborn, Carol J. ;

Park, Yun-Yong ;

Erez, Baruch ;

Jacoby, Joerg J. ;

Lee, Ju-Seog ;

Lin, Heather Y. ;

Ciardiello, Fortunato ;

Herbst, Roy S. ;

Langley, Robert R. ;

Heymach, John V. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (04) :1313-1328

[6] Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies [J].

Crawford, Yongping ;

Ferrara, Napoleone .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (12) :624-630

[7] PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment [J].

Crawford, Yongping ;

Kasman, Ian ;

Yu, Lanlan ;

Zhong, Cuiling ;

Wu, Xiumin ;

Modrusan, Zora ;

Kaminker, Josh ;

Ferrara, Napoleone .

CANCER CELL, 2009, 15 (01) :21-34

[8] Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy [J].

Ebos, John M. L. ;

Lee, Christina R. ;

Kerbel, Robert S. .

CLINICAL CANCER RESEARCH, 2009, 15 (16) :5020-5025

[9] Pathways Mediating Resistance to Vascular Endothelial Growth Factor - Targeted Therapy [J].

Ellis, Lee M. ;

Hicklin, Daniel J. .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6371-6375

[10] Opinion - Angiogenesis: an organizing principle for drug discovery? [J].

Folkman, Judah .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (04) :273-286

← 1 2 3 →